Articles From: OpenText CEO Mark J. Barrenechea to Present at Upcoming Investor Conferences to OPKO Granted Patent from European Patent Office for Lagova™


2014/8/27
WATERLOO, Ontario , Aug.
Sign-up for OpenText CEO Mark J. Barrenechea to Present at Upcoming Investor Conferences investment picks
OpenText Intelligent Growth Strategy Drives Record Fourth Quarter and Fiscal Year 2014 Financial Results Appoints John Doolittle Chief Financial Officer Canada NewsWire WATERLOO, Ontario , July 30, 2014 /CNW/ -- Open Text Corporation (NASDAQ: OTEX) (TSX: OTC) announced today its financial results for the fourth quarter and fiscal year ended June 30, 2014, and the appointment of John Doolittle as Chief Financial Officer.
Sign-up for OpenText Intelligent Growth Strategy Drives Record Fourth Quarter and Fiscal Year 2014 Financial Results Appoints John Doolittle Chief Financial Officer investment picks
WATERLOO, Ontario , July 30, 2014 /PRNewswire/ -- Open Text Corporation (NASDAQ: OTEX) (TSX: OTC) announced today its financial results for the fourth quarter and fiscal year ended June 30, 2014, and the appointment of John Doolittle as Chief Financial Officer.
Sign-up for OpenText Intelligent Growth Strategy Drives Record Fourth Quarter and Fiscal Year 2014 Financial Results Appoints John Doolittle Chief Financial Officer investment picks
Data Processed, Rendered and Delivered Entirely within Europe Alleviates Data Sovereignty Concerns for OpenText Fax2Mail and Production Messaging Customers WATERLOO, Ontario , Aug.
Sign-up for OpenText Launches European Data Zone for Cloud Fax Services investment picks
eDOCS DM 10 Improves Collaboration, Organization and Control for Case Information WATERLOO, Ontario , Aug.
Sign-up for OpenText Launches Next Version of Document Management to Simplify Content Exchange for the Legal Industry investment picks
GS1 Hong Kong's ezTRADE Runs on OpenText Trading Grid Platform to Provide Region's Enterprises Access to the World's Largest Integration Cloud HONG KONG , Aug.
Sign-up for OpenText Powers Hong Kong's Leading EDI Platform investment picks
WATERLOO, Ontario , July 3, 2014 /PRNewswire/ -- Open Text™ Corporation (NASDAQ:OTEX) (TSX:OTC) , today announced that financial results for its fourth quarter and fiscal year 2014 will be released on Wednesday, July 30, 2014 at approximately 4:00 p.m. ET .
Sign-up for OpenText to Report Fourth Quarter and Fiscal Year 2014 Financial Results on Wednesday, July 30, 2014 investment picks
2014/6/24
Combined platforms to reach more than 700 million consumers globally SAN MATEO, Calif.
Sign-up for Opera acquires AdColony to become the world's leading mobile video ad platform investment picks
2014/7/24
ESCONDIDO, Calif.
Sign-up for Operating Results For Second Quarter And First Six Months Of 2014 Announced By Realty Income investment picks
2014/8/11
Program Made Possible by Dollar Tree, SAIC, RetailMeNot, eBags, Veterans United Foundation, and Eckrich SAN ANTONIO , Aug.
Sign-up for Operation Homefront Recognizes Back-to-School Brigade Sponsors investment picks
Operation Homefront and Meritage Homes Corporation (NYSE: MTH) have selected three military families to receive newly-built mortgage-free homes.
Sign-up for Operation Homefront Selects Three Veterans for Mortgage-Free Homes from Meritage Homes investment picks
2014/8/21
Operational Performance Leads to Cash Generation, Dividend Payments and Further Debt Reduction Canada NewsWire JOHANNESBURG , Aug.
Sign-up for Operational Performance Leads to Cash Generation, Dividend Payments and Further Debt Reduction investment picks
2014/8/21
JOHANNESBURG , August 21, 2014 /PRNewswire/ -- Gold Fields Limited (Gold Fields) (JSE, NYSE, NASDAQ Dubai: GFI) today announced normalised earnings from continuing operations for the June 2014 quarter of US$25 million compared with US$21 million for the March 2014 quarter and losses of US$36 million for the June 2013 quarter.
Sign-up for Operational Performance Leads to Cash Generation, Dividend Payments and Further Debt Reduction investment picks
2014/7/5
BERWICK, Pa.
Sign-up for Operators Reconnect Unit 2 at Susquehanna Nuclear Power Plant investment picks
2014/9/15
BERWICK, Pa.
Sign-up for Operators Reconnect Unit 2 at Susquehanna Nuclear Power Plant investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of secondary progressive multiple sclerosis (SPMS), today announced that the Company will report financial results for the three months ended June 30, 2014 after the close of trading on Thursday, August 14th.
Sign-up for Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2014 Financial Results investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced its addition to the Russell Microcap ® Index.
Sign-up for Opexa Therapeutics Joins Russell Microcap Index investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of Multiple Sclerosis (MS), today reported financial results for the second quarter ended June 30, 2014 and provided an overview of the Company’s recent corporate developments.
Sign-up for Opexa Therapeutics Reports Second Quarter 2014 Financial Results and Provides Corporate Update investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K.
Sign-up for Opexa Therapeutics to Present at September Conferences investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® ( imilecleucel-T ), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today disclosed that the Company has commenced development in a second indication, Neuromyelitis optica (NMO). NMO is a rare autoimmune disorder, which is designated as an Orphan disease by the U.S. Food and Drug Administration (FDA). There is currently no cure and there are no FDA approved therapies for this disease.
Sign-up for Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten public offering.
Sign-up for Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock investment picks
LONDON-- Oil explorer Ophir Energy PLC (OPHR.LN) Thursday announced a shake up of its board including the appointment of former Chevron Corp (CVX) executive Bill Higgs as Chief Operating Officer and the departure of Lisa Mitchell as Chief Financial Officer.
Sign-up for Ophir Energy Appoints New COO, CFO Steps Down investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD). This enrollment milestone payment from Novartis was triggered as a result of Ophthotech reaching the first enrollment goal under the agreement in its pivotal, multi-national Fovista ® Phase 3 clinical program and is the first of a total of $130 million in potential enrollment-based milestones under the agreement.
Sign-up for Ophthotech Corporation Achieves $50 Million Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista® investment picks
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the second quarter ended June 30, 2014, on Wednesday, August 6, 2014.
Sign-up for Ophthotech Corporation to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014 investment picks
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Sign-up for Ophthotech Corporation to Present at the 2014 Morgan Stanley Global Healthcare Conference investment picks
2014/8/5
Ophthotech Corporation announced today the initiation of the first of several planned expansion trials, in addition to the ongoing Fovista ® combination therapy Phase 3 clinical program.
Sign-up for Ophthotech Initiates First of Several Expansion Studies to Further Evaluate Fovista® (Anti-PDGF) Therapy in Patients with Wet Age-Related Macular Degeneration investment picks
Ophthotech Corporation (Nasdaq:OPHT) today provided an update on the Company’s business and announced financial results for the second quarter ended June 30, 2014.
Sign-up for Ophthotech Reports Second Quarter 2014 Financial Results and Provides Business Update investment picks
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced 6 month results of a Phase 2 dose-finding study evaluating the safety and efficacy of its novel long-acting human growth hormone product (Lagova) to treat pediatric growth hormone deficiency disorder (GHD). All three Lagova once-weekly doses demonstrate strong catch-up growth during the six months treatment.
Sign-up for OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder investment picks
OPKO Health, Inc. (NYSE:OPK) , a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its second quarter ended June 30, 2014.
Sign-up for OPKO Announces Second Quarter Operating and Financial Results investment picks
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced that the European Patent Office granted OPKO a patent covering the company’s long-acting CTP-enhanced human growth hormone product (Lagova), including composition of matter and associated methods.
Sign-up for OPKO Granted Patent from European Patent Office for Lagova™ investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: OpenText CEO Mark J. Barrenechea to Present at Upcoming Investor Conferences to OPKO Granted Patent from European Patent Office for Lagova™
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices